1356992-95-4
Chemical Structure
Ertapenem-d4
Synonym(s): MK-0826-d4
- CAS No.: 1356992-95-4
- Formula:C22H21D4N3O7S
- Molecular Weight:479.54
InChIKey: JUZNIMUFDBIJCM-MIJLCSPPSA-N
SMILES: OC(C1=C(S[C@H]2C[C@H](NC2)C(NC3=C([2H])C(C(O)=O)=C([2H])C([2H])=C3[2H])=O)[C@H](C)[C@@]([C@@]4([H])[C@H](O)C)([H])N1C4=O)=O
Biological Activity: Ertapenem-d4 (MK-0826-d4) is deuterium labeled Ertapenem. Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ertapenem-d4 | Ertapenem-d4 (MK-0826-d4) is deuterium labeled Ertapenem. Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ertapenem | Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Kenneth E Aldridge. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis. 2002 Oct;44(2):181-6. [Content Brief]
